Montek (Sodium Molybdate (99mo))

• Sodium Molybdate is used to address molybdenum deficiency and to support enzymatic functions that depend on this trace element.
• Molybdenum deficiency: restores normal activity of molybdenum‑dependent enzymes such as sulfite oxidase.
• Parenteral nutrition: supplies essential molybdenum in total nutrient admixtures for patients receiving intravenous feeding.
• Ophthalmic procedures: used as an adjunct in certain ocular solutions to maintain trace‑element balance.

• Sodium molybdate dissociates to release molybdate ions, which are incorporated into the molybdenum cofactor (MoCo). MoCo is required for the catalytic activity of enzymes including sulfite oxidase, xanthine oxidase and aldehyde oxidase. By supplying molybdenum, the drug enables these enzymes to catalyze oxidation–reduction reactions essential for sulfur‑amino‑acid metabolism, purine catabolism and detoxification pathways.

Sodium Molybdate may be associated with adverse reactions, most of which are related to its route of administration or individual sensitivity.

Common Side Effects

• Injection site pain: mild discomfort at the intravenous insertion site.
• Transient erythema: temporary redness around the injection area.
• Headache: mild to moderate headache reported in some patients.
• Nausea: occasional nausea following intravenous administration.
• Ocular irritation: mild burning or stinging sensation when used in eye drops.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergic response requiring immediate medical attention.
• Hypotension: sudden drop in blood pressure after rapid intravenous infusion.
• Renal impairment: worsening kidney function in susceptible individuals.
• Thrombophlebitis: inflammation of the vein with clot formation at the infusion site.

When using Sodium Molybdate, clinicians should observe specific safety measures to minimize risk.

• Allergy assessment: verify no known hypersensitivity to molybdenum compounds.
• Renal function monitoring: evaluate kidney function before and during therapy.
• Infusion rate control: administer intravenously over the recommended time to avoid hypotension.
• Concurrent copper therapy: monitor copper status as excess molybdenum may interfere with copper metabolism.
• Pregnancy and lactation: use only if the potential benefit outweighs risk, as safety data are limited.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Sodium Molybdate can interact with certain agents, affecting its efficacy or safety.

Major Interactions (Avoid)

• High-dose copper supplements: may reduce molybdenum absorption and effectiveness.
• Anticoagulants (e.g., warfarin): increased risk of bleeding if molybdenum alters vitamin K metabolism (theoretical).
• Chemotherapeutic agents that rely on aldehyde oxidase: potential alteration of drug activation.

Moderate Interactions (Monitor Closely)

• Renal‑clearing drugs (e.g., aminoglycosides): monitor renal function as both may affect kidney.
• Diuretics that cause electrolyte shifts: observe for changes in molybdenum levels.
• Vitamin B12 therapy: monitor for possible competitive enzyme interactions.